`
`RESEARCH
`
`APPLICA TION NUMBER:
`
`22-350
`
`RISK ASSESSMENT and RISK MITIGATION
`
`'
`
`REVIEW(S)
`
`
`
`
`
`Department of Health and Human Services
`Public Health Service
`
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Office of Surveillance and Epidemiology
`
`June 22, 2009
`
`Mary Parks, MD, Director
`
`Division of Metabolism and. Endocrine Drug
`Products (DMEP)
`
`Through:
`
`Jodi Duckhorn, MA, Team Leader
`
`From :
`
`Subject:
`
`Division of Risk Management
`
`Jessica M. Diaz, RN, BSN
`
`Patient Product Information Reviewer
`
`Division of Risk Management
`
`DRISK Review of Patient Labeling (Patient
`Package Insert)
`
`Drug Name(s):
`
`ONGLYZA (saxagliptin)
`
`Application
`Type/Number:
`
`NDA 22—350
`
`Applicant/sponsor:
`
`Bristol—Myers Squibb Company
`
`OSE RCM #:
`
`2008—1199
`
`
`
`1
`
`INTRODUCTION
`
`Bristol—Myers Squibb Company submitted NDA 22-350 on June 30,
`2008 as a new molecular entity (NME), saxagliptin. The Division of
`Medication Error Prevention and Analysis (DMEPA) was consulted on
`June 11, 2008 to review proprietary name, Onglyza. The consult was
`received by Division of Metabolism and Endocrine Products (DMEP)
`on July 23, 2008 to review the label and labeling for Onglyza.
`
`A submission was sent by Bristol—Myers Squibb Company on April 9,
`2009 for this NDA with revised labeling changes based on the
`comments from the review division on February 11, 2009. DMEP
`requested that the Division of Risk Management (DRISK) review the
`patient labeling that was submitted as part of the labeling for this
`NDA. This review is written in response to that request.
`
`2 MATERIAL REVIEWED
`
`- ONGLYZA Patient Package Insert (PPI) revised submission from
`April 9, 2009
`
`- ONGLYZA Prescribing Information .(PI) revised submission from
`April 9, 2009, and revised by the Review Division throughout the
`current review cycle.
`
`3 DISCUSSION
`
`The purpose of patient directed labeling is to facilitate and enhance
`appropriate use and provide important risk information about
`medications. Our recommended changes are consistent with current
`research to improve risk communication to a broad audience, including
`those with lower literacy.
`
`Content and formatting revisions are made to ensure that the
`information is legible, clear, and patient-friendly. Patient Information
`that is well designed and clearly worded can help to maximize patient
`use and understanding of important safety information that is
`presented.
`
`The draft PPI submitted by the Applicant has a Flesch Kinkaid grade
`level of 8.8, and a Flesch Reading Ease score of 57.3%. To enhance
`patient comprehension, materials should be written at a 6th to 8th grade
`reading level, and have a reading ease score of at least 60% (60%
`corresponds to an 8th grade reading level). The reading scores as
`submitted by the Applicant are acceptable.
`
`In our review of the PPI, we have:
`
`
`
`.
`.
`.
`.
`
`simplified wording and clarified concepts where possible,
`ensured that the PPI is consistent with the PI,
`removed unnecessary or redundant information
`ensured that the PPI meets the criteria as specified in FDA’s
`Guidance for Useful Written Consumer Medication Information
`(published July 2006).
`
`In 2008, The American Society of Consultant Pharmacists Foundation in
`collaboration with The American Foundation for the Blind published
`Guidelines for Prescription Labeling and Consumer Medication
`Information for People with Vision Loss; They recommend using fonts
`such as Arial, Verdana, or APHont to make medical information more
`accessible for patients with low vision. We have reformatted the PPI
`document using the font APHont, which was developed by the American
`, Printing House for the Blind specifically for low vision readers.
`
`See the attached document for our recommended revisions to the PPI.
`Comments to the review division are bolded, underlined and italicized.
`
`We are providing the review division a marked—up and clean copy of the
`revised PPI. We recommend using the clean copy as the working
`document.
`
`All future relevant changes to the PI should also be reflected in the PPI.
`
`4 CONCLUSIONS AND RECOMMENDATIONS
`
`1. The Applicant uses both the terms “doctor,” and “healthcare
`provider” in the proposed PPI. We recommend that one term be
`used consistently throughout the PPI.
`In the section “What is ONLGYZAQ ‘
`. we have deleted “
`'
`’
`‘
`’
`
`' 2'”:
`
`‘
`
`‘
`” ‘
`
`’
`
`D
`. we recommend moving the disease specific information to the
`end of the PPI or preferably address disease related
`information with patient individually.
`2. In the section “Who should not take ONGLYZA?” we have:
`
`. moved the section “ONGLYZA should not be used to treat" to
`the section “What should I tell my doctor before taking
`ONGLYZA?” to be consistent with placement of this information
`in patient labeling.
`
`
`
`. deleted the section C
`
`23
`3. In the section “What should I tell my doctor before taking
`ONGLYZA?” we have:
`
`.
`
`added “Know the medicines you take. Keep a list of your
`medicines and show it to your healthcare provider and
`pharmacist when you get a new medicine” as this is standard
`language in patient information.
`. deleted C
`_ .
`"
`4"
`"“
`have instead moved this information to the section “How
`
`_
`
`3We
`
`should I take ONGLYZA?" which is typically used for drug
`Dosage and Administration.
`. we moved the signs and symptoms that may require a need to
`change the patient’s medication to the section “How should I
`take ONGLYZA?” because this section includes information
`from Dosage and Administration section of PI.
`. we recommend not including a long list of drugs with single
`brand names because if the brand name of the patient’s
`medicine is not included, they may think that their medicine is
`“safe”.
`
`4. In the section “How should I take ONGLYZA?" we have:
`. deleted C
`’
`included in the section “What should I tell my healthcare
`provider before taking ONGLYZA?".
`added the symptoms associated with possible changes in
`medication dose
`'
`
`.
`
`. D
`
`.
`
`added “Follow your healthcare provider’s instructions for
`treating low blood sugar. Talk to your healthcare provider if
`low blood sugar is a problem for you."
`5. In the sections "C
`
`3 Patient
`_
`labeling is to convey product-specific information, not disease or
`condition-specific information.
`We recommend this information be discussed with the patient
`during his/her appointment with the healthcare provider.
`
`11(4) K
`
`11(4)
`
`
`
`6. In the section, “What are the possible side effects of ONGLYZA?"
`we have:
`
`.
`
`added “ONGLYZA may cause serious side effects including:",
`which corresponds to the “Warnings and Precautions”
`section in PI.
`
`. Added “kidney problems” and “low blood sugar
`(hypoglycemia)” because the PI recommends close
`adjustments for moderate or severe renal impairment/ESRD
`and a lower dose of ONGLYZA when used with
`
`sulfonylureas.
`. Under “most common side effects of ONGLYZA” added
`peripheral edema “swelling of hand and feet" to be
`consistent with the PI.
`
`. Removed the section that é
`
`7. In the section, “How should I store ONGLYZA?” we have inserted
`the range of temperatures as listed in the PI instead of “room
`temperature” because it provides a quantitative range. “Room
`temperature" can be interpreted differently by people.
`
`J
`
`Please let us know if you have any questions.
`
`
`
`This is a representation of an electronic record that was signed electronically and
`this page is the manifestation of the electronic signature.
`
`.
`Jessica Diaz
`6/22/2009 10:24:46 AM
`LABELING REVIEWER
`
`Jodi Duckhorn
`6/22/2009 11:02:07 AM
`DRUG SAFETY OFFICE REVIEWER
`
`